| Immune checkpoint therapy—current perspectives and future directions P Sharma, S Goswami, D Raychaudhuri, BA Siddiqui, P Singh, ... Cell 186 (8), 1652-1669, 2023 | 164 | 2023 |
| Cutting edge: Piezo1 mechanosensors optimize human T cell activation CSC Liu, D Raychaudhuri, B Paul, Y Chakrabarty, AR Ghosh, ... The Journal of Immunology 200 (4), 1255-1260, 2018 | 124 | 2018 |
| Lactate induces pro-tumor reprogramming in intratumoral plasmacytoid dendritic cells D Raychaudhuri, R Bhattacharya, BP Sinha, CSC Liu, AR Ghosh, ... Frontiers in immunology 10, 1878, 2019 | 101 | 2019 |
| Adipose recruitment and activation of plasmacytoid dendritic cells fuel metaflammation AR Ghosh, R Bhattacharya, S Bhattacharya, T Nargis, O Rahaman, ... Diabetes 65 (11), 3440-3452, 2016 | 97 | 2016 |
| Myeloid cell-targeted therapies for solid tumours S Goswami, S Anandhan, D Raychaudhuri, P Sharma Nature Reviews Immunology 23 (2), 106-120, 2023 | 91 | 2023 |
| A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19 Y Ray, SR Paul, P Bandopadhyay, R D’Rozario, J Sarif, D Raychaudhuri, ... Nature Communications 13 (1), 383, 2022 | 31 | 2022 |
| A chemical switch for transforming a purine agonist for toll-like receptor 7 to a clinically relevant antagonist A Mukherjee, D Raychaudhuri, BP Sinha, B Kundu, M Mitra, B Paul, ... Journal of Medicinal Chemistry 63 (9), 4776-4789, 2020 | 21 | 2020 |
| Systematic optimization of potent and orally bioavailable purine scaffold as a dual inhibitor of toll-like receptors 7 and 9 B Kundu, D Raychaudhuri, A Mukherjee, BP Sinha, D Sarkar, ... Journal of Medicinal Chemistry 64 (13), 9279-9301, 2021 | 16 | 2021 |
| Cutting edge: dysregulated endocannabinoid-rheostat for plasmacytoid dendritic cell activation in a systemic lupus endophenotype O Rahaman, R Bhattacharya, CSC Liu, D Raychaudhuri, AR Ghosh, ... The Journal of Immunology 202 (6), 1674-1679, 2019 | 16 | 2019 |
| Activity-guided development of potent and selective toll-like receptor 9 antagonists B Paul, O Rahaman, S Roy, S Pal, S Satish, A Mukherjee, AR Ghosh, ... European Journal of Medicinal Chemistry 159, 187-205, 2018 | 16 | 2018 |
| Plasma gradient of soluble urokinase-type plasminogen activator receptor is linked to pathogenic plasma proteome and immune transcriptome and stratifies outcomes in severe COVID-19 J Sarif, D Raychaudhuri, R D’Rozario, P Bandopadhyay, P Singh, ... Frontiers in Immunology 12, 738093, 2021 | 14 | 2021 |
| Circulating interleukin-8 dynamics parallels disease course and is linked to clinical outcomes in severe COVID-19 R D’Rozario, D Raychaudhuri, P Bandopadhyay, J Sarif, P Mehta, ... Viruses 15 (2), 549, 2023 | 5 | 2023 |
| Clinical trial subgroup analyses to investigate clinical and immunological outcomes of convalescent plasma therapy in severe COVID-19 D Raychaudhuri, P Bandopadhyay, R D’Rozario, J Sarif, Y Ray, SR Paul, ... Mayo Clinic Proceedings: Innovations, Quality & Outcomes 6 (6), 511-524, 2022 | 4 | 2022 |
| Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade S Goswami, D Raychaudhuri, P Singh, SM Natarajan, Y Chen, C Poon, ... Nature Cancer 4 (10), 1455-1473, 2023 | 3 | 2023 |
| Role of Ca2+ in toll-like receptor 9 activation in human plasmacytoid dendritic cells D Raychaudhuri, P Duttagupta, CSC Liu, J Sarif, AR Ghosh, O Rahaman, ... Cytokine 125, 154822, 2020 | 3 | 2020 |
| Histone Lactylation Drives CD8 T Cell Metabolism and Function D Raychaudhuri, P Singh, M Hennessey, AJ Tannir, B Chakraborty, ... bioRxiv, 2023.08. 25.554830, 2023 | 1 | 2023 |
| Lung epithelial response to SARS-CoV2 and diabetes D Ganguly Authorea Preprints, 2020 | | 2020 |
| Purine based compounds as toll-like receptor 9 antagonist A Talukdar, D Ganguly, A Mukherjee, B Paul, O Rahaman, B Kundu, ... US Patent App. 16/760,727, 2019 | | 2019 |
